)
)
)
Synklino
March 02, 2026
Ballroom I C
Type: Company Presentation
Focus Area:
Infectious Diseases
Synklino is a clinical stage biotechnology company pioneering transformative therapies for solid organ transplantation. Our first-in-class breakthrough drug candidate, SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients. Following recent regulatory approval, SYN002 is set to enter clinical development in kidney transplantation in in the coming months.
Year Founded:
2017
Lead Product in Development:
SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
